Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
reductase/inflamació
L'enllaç es desa al porta-retalls
Pàgina 1 des de 41 resultats
Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
The present invention relates to the combination of certain known therapeutic compounds for therapeutic purposes. The substances used in the combinations according to the invention are known active agents from the phosphodiesterase 4 (PDE4) inhibitor class and active agents from the
Combination method of treating acne using 4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-androstan-ones as selective 5.alpha.-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
The present invention is directed to a combination method for treating ache using selective 5.alpha.-reductase 1 inhibitors, 5.alpha.-reductase 2 inhibitors, combinations thereof, or dual inhibitors, including but not limited to:
Sepiapterin reductase inhibitors
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Tetrahydrobiopterin (BH4) is an enzyme cofactor for various aromatic amino acid hydroxylases, including phenylalanine, tyrosine and tryptophan hydroxylases, as well as being an important cofactor for other enzymes such as the nitric oxide synthases (inducible NOS (iNOS), endothelial NOS
Methods involving aldose reductase inhibitors
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
I. Field of the Invention
Embodiments of this invention are related generally to physiology and medicine. More specifically, this invention is related to aldose reductase inhibitors (ARIs) and their use in treating and ameliorating inflammation.
II. Background
Aldose
Methods involving aldose reductase inhibitors
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
I. Field of the Invention
Embodiments of this invention are related generally to physiology and medicine. More specifically, this invention is related to aldose reductase inhibitors (ARIs) and their use in treating and ameliorating inflammation.
II. Background
Aldose
Methods involving aldose reductase inhibitors
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
I. Field of the Invention
Embodiments of this invention are related generally to physiology and medicine. More specifically, this invention is related to aldose reductase inhibitors (ARIs) and their use in treating and ameliorating inflammation.
II. Background
Aldose
Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
The pro-inflammatory cytokines, such as tumor necrosis factor-.alpha. (TNF-.alpha.) and interleukin-1.beta. (IL-1.beta.), contribute to the pathogenesis of various allergic, inflammatory and autoimmune diseases. Consequently, multiple therapeutic approaches have been aimed at reducing the
Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
The pro-inflammatory cytokines, such as tumor necrosis factor-.alpha. (TNF-.alpha.) and interleukin-1.beta. (IL-1.beta.), contribute to the pathogenesis of various allergic, inflammatory and autoimmune diseases. Consequently, multiple therapeutic approaches have been aimed at reducing the
Sepiapterin reductase inhibitors for the treatment of pain
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
In general, the present invention relates to small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and to the medical use of these compounds.
Tetrahydrobiopterin (BH4), which has the following structure,
##STR00001## is an essential cofactor of
Sepiapterin reductase inhibitors for the treatment of pain
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
In general, the present invention relates to small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and to the medical use of these compounds.
Tetrahydrobiopterin (BH4), which has the following structure,
##STR00001## is an essential cofactor of
Materials and methods for inhibiting mamalian S-nitrosoglutathione reductase
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
Various aspects and embodiments relate generally to materials and methods for inhibiting the enzyme S-nitrosoglutathione reductase (GSNOR) and for diagnosing, studying and treating various conditions and diseases related to the activity of this enzyme.
BACKGROUND
S-nitrosylation of
Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF RELATED ART
1. Technical Field
The present disclosure relates to the treatment of cancer. More particularly, the disclosed invention relates to the use of novel bi-functional inhibitors against histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
Pharmaceutical composition and method for inhibiting inflammation
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This application claims priority to Taiwan Patent Application No. 099137186 filed on Oct. 29, 2010.
FIELD
The present invention relates to a pharmaceutical composition for inhibiting inflammation, especially to a pharmaceutical composition useful for arthritis.
BACKGROUND
Arthritis is a common
Metabolically inert anti-inflammatory and anti-tumor antifolates
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF INVENTION
This invention relates to folic acid antagonists that are metabolically inert exhibiting a high level of anti-inflammatory and anti-tumor activity. Metabolically inert classical antifolates are new and therefore they exhibit unexpected biological properties such as those recited
Heterocyclic amine-boranes, and method of inhibiting DNA topoisomerase activity and/or combatting inflammation, hyperlipidemia, and/or neoplasia using amine-borane compounds
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to amine-borane compounds, including novel heterocyclic amine-boranes, and to a method of inhibiting enzyme (e.g., DNA topoisomerase) activity and/or combatting inflammation, hypolipidemia and/or neoplasia using
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
